OCB are presenting today with IBM at Pharmatec19 – London Room 7 at 11:20: Using AI Technology To Improve Outcomes For Cancer Patients
Today 25 September 2019, OCB are presenting with IBM at Pharmatec19 – London Room 7 at 11:20 – Using AI Technology
Oxford Cancer Biomarkers appoints a Medical Science Liaison Manager to strengthen operations and support continued growth
Oxford Cancer Biomarkers (OCB) have made another key appointment. The company has hired a Medical Science Liaison Manager to strengthen
Oxford Cancer Biomarkers hires two Senior Operations and Quality Control Specialists to help manage continued growth
For immediate release: 22 August 2019 Oxford Cancer Biomarkers (OCB) have hired two Senior Operations and Quality Control Specialists to
Oxford Cancer Biomarkers Ltd. and Oxford University Hospitals offer genetic testing to prevent 5-FU/capecitabine toxicity
Oxford, 21st June 2019: Oxford University Hospitals (OUH) NHS Foundation Trust is now offering genetic testing that aims to
PRESS RELEASE: Oxford, UK and South Korea, 3rd June 2019: KwangDong Pharmaceutical Co. Ltd and Oxford Cancer Biomarkers Ltd. agree a significant investment partnership
Oxford Cancer Biomarkers (OCB) has gained a significant investment from leading South Korean healthcare company KwangDong Pharmaceutical Co. Ltd. (KDP).
30/May/19 Last Friday (May 24th) Dr Xu, our Chief Software Engineer, gave an academic report on “Diagnosis, Prognosis and Predicting Biomarkers of
We are grateful to Rebecca for writing this and for her participation in the continuous improvement in our ToxNav® panel.